key: cord-0809195-x1dlvjgr
authors: Siskind, Dan; Northwood, Korinne; Berk, Michael; Castle, David; Galletly, Cherrie; Harris, Anthony
title: Monitoring for post-injection delirium/sedation syndrome with long-acting olanzapine during the COVID-19 pandemic
date: 2020-05-14
journal: Aust N Z J Psychiatry
DOI: 10.1177/0004867420927465
sha: d6152f8381f1a0e794aae7c76afef63237f6b4c1
doc_id: 809195
cord_uid: x1dlvjgr

nan

To the Editor Olanzapine long-acting injectable (LAI), licensed in Australia for treatment of schizophrenia, improves medication adherence and prevents illness relapse (Kane et al., 2010) . During premarketing clinical trials, in 0.07% of injections , olanzapine LAI administration was associated with post-injection delirium/sedation syndrome (PDSS). Symptoms and signs include acute sedation, delirium, slurred speech, ataxia and/or altered level of consciousness. It is caused by incidental injection into a venule during intramuscular administration. The median time to onset of initial signs and symptoms is 25 minutes (interquartile range, 12-60 minutes; Kane et al., 2010) . Current monitoring guidelines recommend active monitoring of alertness every 30 minutes for 2 hours post-injection.

Given the current COVID-19 precautions, physical distancing requirements and resource constraints, 2-hour monitoring may not be feasible; however, cessation of olanzapine LAI is likely to lead to relapse of psychotic symptoms. Using publicly available data, we explored the post-marketing incidence of PDSS in Australian patients receiving olanzapine LAI, in order to assist in decision making around monitoring.

We included all 74,960 olanzapine LAI dispensings listed in the Pharmaceutical Benefits Schedule (PBS) database from the introduction of olanzapine LAI in January 2010 until the end of January 2020. Adverse event reports for all olanzapine formulations (and the subset of olanzapine LAI) were drawn from Australian Therapeutic Goods Association Database of Adverse Event Notifications (DAEN).

A total of 772 DAEN reports were related to all formulations of olanzapine, with 112 specifically linked to olanzapine LAI. All reports were reviewed for symptoms and signs associated with PDSS. For all formulations of olanzapine, rates of PDSS ranged from 0.03% of all injections when PDSS was specified in the DAEN report to 0.11% of all injections when all potential PDSS signs and symptoms were included (Table 1) .

There are several caveats to interpreting this data. PBS can only provide dispensing data, which may be slightly higher than actual injections (Page et al., 2015) . Only events per dispensing can be calculated, not events per patient. The PBS database does not capture any non-PBS subsidised prescriptions; however, this number is likely to be very low for LAI olanzapine. DAEN is a voluntary database and although most serious adverse events such as PDSS are usually reported to DAEN, it may not capture all events. These data suggest that PDSS following olanzapine LAI injection is rare. The benefits of continuing access to a medication that reduces risk of relapse and decreases time in patient waiting rooms with their associated risk of exposure to infectious disease may outweigh the risk of developing PDSS. In situations where 2-hour monitoring is unsafe or unfeasible, it may be worth considering reducing the monitoring period to 30 minutes to an hour, or temporarily removing the clinical staff monitoring requirement for appropriate patients who have a responsible person to assist in supervision post-injection. He has received payments for educational sessions run for Janssen Australia and Lundbeck Australia. He has developed educational material for Servier. He is also the recipient of an investigator-initiated grant from Takeda Pharmaceutical Company.

The author(s) received no financial support for the research, authorship and/or publication of this article.

Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, I: Analysis of cases

Olanzapine long-acting injection: A 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia

Using Australian pharmaceutical benefits scheme data for pharmacoepidemiological research: Challenges and approaches